MyFinsight
Home
Blog
About
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$32,315K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of inve...
Trade receivables, net
Prepaids and other current and n...
Others
Negative Cash Flow Breakdown
Tsa related operating assets and...
Net income (loss)
Purchases of investments in mark...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-20,631
-38,327
-37,643
-35,531
Depreciation and amortization
862
881
896
966
Stock-based compensation expense
2,583
2,385
2,784
3,389
Impairment of out-license asset and remeasurement of cvr liability, net
-
-
-
1,646
Write-down of intangible assets and remeasurement of contingent consideration liabilities, net
-
-
4,164
-
Loss on debt extinguishment
-
-
0
-10,286
(gain) loss on sale transactions, net (note 6)
-311
-388
-365
-422
Change in fair value of derivatives
-
-
0
0
Other non-cash adjustments, net
-12,498
468
-4,976
-7,842
Trade receivables, net
-8,222
4,282
8,338
4,266
Inventory
-437
11,312
1,114
-2,480
Prepaid manufacturing
-
-4,485
-1,290
1,348
Prepaids and other current and non-current assets
-7,639
3,071
-2,367
-3,274
Accounts payable
1,689
2,564
-5,088
-15,301
Accrued rebates, fees and reserves
-734
-1,631
-30,213
-21,061
Tsa related operating assets and liabilities, net
38,871
3,303
-51,805
-23,188
Accrued compensation
-5,332
33
1,194
2,370
Accrued and other current and non-current liabilities
-1,282
-7,164
4,437
1,275
Net cash used in operating activities
-62,090
-57,886
-19,716
-46,339
Purchases of investments in marketable securities
13,897
6,388
14,262
68,850
Proceeds from maturities of investments in marketable securities
43,536
38,135
19,812
1,650
Net cash received related to the sale transactions (note 6)
-
-
8,376
0
Milestone payments to junshi biosciences
-
-
0
0
Other investing activities, net
8
1,092
12
27
Net cash provided by investing activities
29,631
30,655
-2,838
-67,227
Proceeds from (repayment of) revenue purchase and sale agreement, net of issuance costs
-
-
0
0
Proceeds from issuance of common stock under private placement, net of issuance costs
-
-
7,894
-
Proceeds from issuance of common stock under public offering, net of issuance costs
0
53,650
-
-
Proceeds from purchases under the employee stock purchase plan
202
-
165
0
Taxes paid related to net share settlement
0
112
0
3
Repayment and redemption of 2026 convertible notes, including transaction costs
121
-
0
0
Other financing activities, net
63
52
22
5
Net cash provided by (used in) financing activities
144
53,590
8,081
2
Net increase (decrease) in cash, cash equivalents and restricted cash
-32,315
26,359
-14,473
-113,564
Cash, cash equivalents and restricted cash at beginning of period
115,478
89,119
103,592
126,250
Cash, cash equivalents and restricted cash at end of period
83,163
115,478
89,119
103,592
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of investments in...
$43,536K
Proceeds from purchases
under the employee...
$202K
(7.45%↑ Y/Y)
Other financing
activities, net
$63K
(107.33%↑ Y/Y)
Net cash provided by
investing activities
$29,631K
(-93.34%↓ Y/Y)
Net cash provided by
(used in) financing...
$144K
(100.05%↑ Y/Y)
Canceled cashflow
$13,905K
Canceled cashflow
$121K
Net increase
(decrease) in cash, cash...
-$32,315K
(-135.55%↓ Y/Y)
Canceled cashflow
$29,775K
Trade receivables,
net
-$8,222K
(92.26%↑ Y/Y)
Prepaids and other
current and non-current...
-$7,639K
(-979.06%↓ Y/Y)
Stock-based compensation
expense
$2,583K
(-76.07%↓ Y/Y)
Accounts payable
$1,689K
(102.76%↑ Y/Y)
Depreciation and
amortization
$862K
(-58.20%↓ Y/Y)
Inventory
-$437K
(-102.37%↓ Y/Y)
(gain) loss on sale
transactions, net (note 6)
-$311K
(-100.09%↓ Y/Y)
Purchases of investments
in marketable...
$13,897K
(-32.95%↓ Y/Y)
Other investing
activities, net
$8K
(-97.36%↓ Y/Y)
Repayment and redemption
of 2026...
$121K
(-99.95%↓ Y/Y)
Net cash used in
operating activities
-$62,090K
(14.31%↑ Y/Y)
Canceled cashflow
$21,743K
Tsa related
operating assets and...
$38,871K
(268.55%↑ Y/Y)
Net income (loss)
-$20,631K
(-108.55%↓ Y/Y)
Other non-cash
adjustments, net
-$12,498K
(-601.93%↓ Y/Y)
Accrued compensation
-$5,332K
(27.25%↑ Y/Y)
something is missing
-$4,485K
Accrued and other
current and non-current...
-$1,282K
(91.40%↑ Y/Y)
Accrued rebates, fees
and reserves
-$734K
(98.92%↑ Y/Y)
Buy us a coffee